{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:17:44Z","timestamp":1793128664917,"version":"4.5.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Clinical tools to guide treatment decisions in relapsed\/refractory mantle cell lymphoma (R\/R MCL) are limited. Moreover, the translational potential of circulating tumor DNA (ctDNA) remains largely unproven. We designed and applied panel-based duplex sequencing of ctDNA to study molecular determinants of response and outcome in 58 patients with R\/R MCL treated with venetoclax, lenalidomide, and rituximab. Genetic analysis revealed molecular predictors of response that were independent of clinical prognostic factors, with SMARCA4-mutated R\/R MCLs responding to therapy, whereas TP53 mutations conferred resistance. Pretreatment ctDNA captured spatial heterogeneity, and its concentration was associated with multiple clinicopathological disease features and survival, independently of molecular predictors. Dynamic ctDNA assessment for minimal residual disease complemented clinical response evaluation and uncovered refractoriness in patients with molecular remission according to contemporary real-time quantitative polymerase chain reaction assay. Features of clonal hematopoiesis (CH) at baseline were associated with hematologic toxicity during treatment and poor outcomes on follow-up. Positive selection of TP53-related CH during treatment did not compromise the specificity of ctDNA response analysis, and fragmentation signatures allowed distinction between MCL ctDNA and CH-bearing cell-free DNA. Taken together, we report novel features in MCL ctDNA that reveal new minimally invasive tools that could potentially transform clinical decision-making in R\/R MCL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025015791","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T10:25:32Z","timestamp":1747909532000},"page":"4528-4541","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Circulating tumor DNA determinants of response and outcome in relapsed\/refractory mantle cell lymphoma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6378-5381","authenticated-orcid":false,"given":"Leo","family":"Meriranta","sequence":"first","affiliation":[{"name":"1Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland"},{"name":"2Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"3iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7249-2196","authenticated-orcid":false,"given":"Rasmus","family":"Rask Kragh J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark"},{"name":"5Center for Clinical Data Science, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Pasanen","sequence":"additional","affiliation":[{"name":"1Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland"},{"name":"2Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"3iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Kolstad","sequence":"additional","affiliation":[{"name":"6Department of Oncology, Innlandet Hospital, Brumunddal, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-1741","authenticated-orcid":false,"given":"Martin","family":"Hutchings","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-5242","authenticated-orcid":false,"given":"Carsten Utoft","family":"Niemann","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-380X","authenticated-orcid":false,"given":"Tarec Christoffer","family":"El-Galaly","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark"},{"name":"8Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"},{"name":"9Department of Hematology, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0024-0093","authenticated-orcid":false,"given":"Jon","family":"Riise","sequence":"additional","affiliation":[{"name":"10Department of Oncology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Haaber","family":"Christensen","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Sonnevi","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Karolinska University Hospital, Stockholm, Sweden"},{"name":"12Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone Bredo","family":"Pedersen","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin Fahl","family":"Wader","sequence":"additional","affiliation":[{"name":"13Department of Oncology, St Olav University Hospital, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-3041","authenticated-orcid":false,"given":"Ingrid","family":"Glimelius","sequence":"additional","affiliation":[{"name":"14Unit of Cancer Precision Medicine, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8265-511X","authenticated-orcid":false,"given":"Sirpa","family":"Lepp\u00e4","sequence":"additional","affiliation":[{"name":"1Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland"},{"name":"2Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"3iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[{"name":"15Division of Oncology, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"issue":"26","key":"2025090911214260500_bib1","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"2025090911214260500_bib2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain","year":"2022","journal-title":"Am J Hematol"},{"issue":"3","key":"2025090911214260500_bib3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"6","key":"2025090911214260500_bib4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1200\/JCO.18.00690","article-title":"Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era","volume":"37","author":"Gerson","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10441","key":"2025090911214260500_bib5","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","article-title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"issue":"suppl_4","key":"2025090911214260500_bib6","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"2025090911214260500_bib7","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.2021013326","article-title":"Therapeutic options for relapsed\/refractory mantle cell lymphoma","volume":"139","author":"Eyre","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025090911214260500_bib8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/bjh.18597","article-title":"Survival of patients with mantle cell lymphoma in the rituximab era: retrospective binational analysis between 2000 and 2020","volume":"201","author":"Harmanen","year":"2023","journal-title":"Br J Haematol"},{"issue":"6","key":"2025090911214260500_bib9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"2025090911214260500_bib10","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"13","key":"2025090911214260500_bib11","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"2025090911214260500_bib12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025090911214260500_bib13","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2025090911214260500_bib14","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbmt.2006.07.007","article-title":"Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma","volume":"12","author":"Ladetto","year":"2006","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"2025090911214260500_bib15","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s11864-023-01102-2","article-title":"Utility of measurable residual disease (MRD) assessment in mantle cell lymphoma","volume":"24","author":"Wu","year":"2023","journal-title":"Curr Treat Options Oncol"},{"issue":"11","key":"2025090911214260500_bib16","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1200\/JCO.21.02321","article-title":"Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, phase II trial","volume":"40","author":"Gin\u00e9","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16","key":"2025090911214260500_bib17","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2025090911214260500_bib18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3324\/haematol.11267","article-title":"Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations","volume":"93","author":"B\u00f6ttcher","year":"2008","journal-title":"Haematologica"},{"issue":"3","key":"2025090911214260500_bib19","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3324\/haematol.2015.134957","article-title":"Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study","volume":"101","author":"Cheminant","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"2025090911214260500_bib20","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"issue":"6","key":"2025090911214260500_bib21","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2025090911214260500_bib22","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"issue":"364","key":"2025090911214260500_bib23","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"issue":"4","key":"2025090911214260500_bib24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2025090911214260500_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/2643-3230.BCD-21-0029","article-title":"Circulating tumor DNA in lymphoma: principles and future directions","volume":"3","author":"Roschewski","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2025090911214260500_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"issue":"8","key":"2025090911214260500_bib27","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/bloodadvances.2021006397","article-title":"Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma","volume":"6","author":"Lakhotia","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"2025090911214260500_bib28","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"issue":"45","key":"2025090911214260500_bib29","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"2025090911214260500_bib30","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells","volume":"123","author":"Zhang","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2025090911214260500_bib31","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2025090911214260500_bib32","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood.2019002385","article-title":"Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing","volume":"136","author":"Pararajalingam","year":"2020","journal-title":"Blood"},{"issue":"12","key":"2025090911214260500_bib33","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"12","key":"2025090911214260500_bib34","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood.2021012852","article-title":"Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma","volume":"139","author":"Meriranta","year":"2022","journal-title":"Blood"},{"issue":"36","key":"2025090911214260500_bib35","doi-asserted-by":"crossref","first-page":"14508","DOI":"10.1073\/pnas.1208715109","article-title":"Detection of ultra-rare mutations by next-generation sequencing","volume":"109","author":"Schmitt","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2025090911214260500_bib36","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/nprot.2014.170","article-title":"Detecting ultralow-frequency mutations by duplex Sequencing","volume":"9","author":"Kennedy","year":"2014","journal-title":"Nat Protoc"},{"issue":"2","key":"2025090911214260500_bib37","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/bloodadvances.2023011920","article-title":"MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial","volume":"8","author":"Jerkeman","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"2025090911214260500_bib38","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"issue":"5","key":"2025090911214260500_bib39","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat Biotechnol"},{"key":"2025090911214260500_bib40","doi-asserted-by":"publisher","DOI":"10.1101\/2020.01.27.912790","article-title":"ctDNAtools: an R package to work with sequencing data of circulating tumor DNA","author":"Alkodsi","year":"28  2020","journal-title":"bioRxiv"},{"issue":"16","key":"2025090911214260500_bib41","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2025090911214260500_bib42","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2025090911214260500_bib43","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/clinchem\/hvaa026","article-title":"Fragment size analysis may distinguish clonal hematopoiesis from tumor-derived mutations in cell-free DNA","volume":"66","author":"Marass","year":"2020","journal-title":"Clin Chem"},{"issue":"7802","key":"2025090911214260500_bib44","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","article-title":"Integrating genomic features for non-invasive early lung cancer detection","volume":"580","author":"Chabon","year":"2020","journal-title":"Nature"},{"issue":"7","key":"2025090911214260500_bib45","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023022353","article-title":"Treatment of relapsed\/refractory MCL","volume":"145","author":"Silkenstedt","year":"2025","journal-title":"Blood"},{"issue":"6","key":"2025090911214260500_bib46","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ajh.25796","article-title":"Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients","volume":"95","author":"Zhao","year":"2020","journal-title":"Am J Hematol"},{"issue":"2","key":"2025090911214260500_bib47","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2352-3026(22)00355-6","article-title":"Treatment approaches for patients with TP53-mutated mantle cell lymphoma","volume":"10","author":"Lew","year":"2023","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2025090911214260500_bib48","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2024-194641","article-title":"Addition or substitution of acalabrutinib in intensive frontline chemoimmunotherapy for patients \u2264 70 years old with mantle cell lymphoma: outcomes of the 3-arm randomized phase II intergroup trial ECOG-ACRIN","volume":"144","author":"Wagner-Johnston","year":"2024","journal-title":"Blood"},{"issue":"12","key":"2025090911214260500_bib49","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat Med"},{"issue":"12","key":"2025090911214260500_bib50","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1038\/s41375-022-01725-8","article-title":"Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL","volume":"36","author":"Husby","year":"2022","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/17\/4528\/2411375\/blooda_adv-2025-015791-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/17\/4528\/2411375\/blooda_adv-2025-015791-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:21:55Z","timestamp":1757431315000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/17\/4528\/537382\/Circulating-tumor-DNA-determinants-of-response-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":50,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,9,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025015791","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,9]]},"published":{"date-parts":[[2025,9,9]]}}}